The convergent development of molecular-targeted drugs for cancer treatment and prevention
- PMID: 17634526
- DOI: 10.1158/1078-0432.CCR-07-0063
The convergent development of molecular-targeted drugs for cancer treatment and prevention
Abstract
Advances in our understanding of multistep and field carcinogenesis are erasing the clear demarcation of intraepithelial neoplasia from invasive neoplasia. The growing ability to define a very high risk of cancer is forging important commonalities between prevention and therapy, such as in potential prognostic/predictive markers, agents, and side effects that patients would be willing to tolerate, and the logistics of definitive trials. The emergence of promising new molecular-targeted agents and new technologies for screening and early detection provides new opportunities for applying clinical trial designs that integrate therapy and prevention end points. Such trials may be used to facilitate targeted drug development and help identify strategies for both cancer prevention and advanced cancer therapy. These several advances are creating a convergence of cancer therapy with cancer prevention that promises to streamline the development of targeted drugs and improve the control of major cancers.
Similar articles
-
Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development.Nat Rev Cancer. 2007 Jul;7(7):508-18. doi: 10.1038/nrc2154. Nat Rev Cancer. 2007. PMID: 17568791 Review.
-
Chemoprevention: from research to clinical oncology.Eur J Cancer. 2005 Sep;41(13):1833-41. doi: 10.1016/j.ejca.2005.06.007. Eur J Cancer. 2005. PMID: 16061373
-
Oral cancer prevention and the evolution of molecular-targeted drug development.J Clin Oncol. 2005 Jan 10;23(2):346-56. doi: 10.1200/JCO.2005.09.128. J Clin Oncol. 2005. PMID: 15637397 Review.
-
The convergence of cancer prevention and therapy in early-phase clinical drug development.Cancer Cell. 2004 Oct;6(4):321-6. doi: 10.1016/j.ccr.2004.09.021. Cancer Cell. 2004. PMID: 15488755 Review.
-
Surrogate end-point biomarkers in chemopreventive drug development.IARC Sci Publ. 2001;154:13-26. IARC Sci Publ. 2001. PMID: 11220652 Review.
Cited by
-
Future directions in cancer prevention.Nat Rev Cancer. 2012 Dec;12(12):835-48. doi: 10.1038/nrc3397. Epub 2012 Nov 15. Nat Rev Cancer. 2012. PMID: 23151603 Review.
-
The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.Gynecol Oncol. 2012 Jan;124(1):134-41. doi: 10.1016/j.ygyno.2011.08.026. Epub 2011 Oct 11. Gynecol Oncol. 2012. PMID: 21996264 Free PMC article.
-
The BATTLE to personalize lung cancer prevention through reverse migration.Cancer Prev Res (Phila). 2011 Jul;4(7):962-72. doi: 10.1158/1940-6207.CAPR-11-0232. Cancer Prev Res (Phila). 2011. PMID: 21733820 Free PMC article.
-
Chemoprevention of head and neck cancer with green tea polyphenols.Cancer Prev Res (Phila). 2010 Aug;3(8):900-9. doi: 10.1158/1940-6207.CAPR-09-0131. Epub 2010 Jul 27. Cancer Prev Res (Phila). 2010. PMID: 20663981 Free PMC article. Review.
-
Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung.Cancer Prev Res (Phila). 2010 Feb;3(2):128-31. doi: 10.1158/1940-6207.CAPR-09-0268. Epub 2010 Jan 26. Cancer Prev Res (Phila). 2010. PMID: 20103726 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
